Amicus Therapeutics (FOLD) Wednesday reported net income of $14.7 million, or $0.05 per share for the fourth quarter, compared with net loss of $33.8 million, or $0.11 per share for the same quarter a year ago.
Excluding one-time items, earnings were $29.2 million or $0.09 per share compared with $2.6 million or $0.01 per share last year.
Product sales grew 30 percent to $149.71 million from $115.08 million in the previous year.
Analysts on average, expected the company to report earnings of $0.09 per share on revenue of $147.87 million. Analysts' estimates typically exclude special items.
For fiscal 2025, the company expects revenue growth in the range of 17 percent - 24 percent. The Street is looking for revenue growth of 20.68 percent. The company also sees positive net income in the second half of 2025.
For comments and feedback: editorial@rttnews.com